ABE (Accelerating Breakthroughs in EB)

🗓 Founded 2023👥 1 employees
Biotechnology Research🌐 abe-bio.com
Website LinkedIn
Epidermolysis Bullsosa (EB) is a painful genetic skin condition that causes the skin to tear or blister at the lightest touch. DEB (Dystrophic EB) is one of the most severe subsets of EB. Our mission is to help patients with EB to live, and to live well. By fulfilling our mission, we can transform the lives of people with DEB, as well as to develop and support technologies that can help cure thousands of other rare diseases that impact ~ 400m people worldwide.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was ABE (Accelerating Breakthroughs in EB) founded?
ABE (Accelerating Breakthroughs in EB) was founded in 2023.
What industry is ABE (Accelerating Breakthroughs in EB) in?
ABE (Accelerating Breakthroughs in EB) operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.